Shots:
- Mirum Pharmaceuticals has entered into an agreement to acquire Bluejay Therapeutics, gaining global rights to brelovitug with Breakthrough Therapy and PRIME designations, and expanding Mirum’s rare liver disease portfolio
- As per the deal, Mirum will acquire all Bluejay shares for $250M in cash and $370M in Mirum stock, plus up to $200M in sales-based milestones. Bluejay shareholders will receive Mirum stock at $71.2085/share
- Mirum will also raise ~$200M via a private placement of common stock and pre-funded warrants at $68.48/share to fund clinical and commercial activities. The deal is expected to close in Q1’26, pending regulatory and customary approvals
Ref: Mirum Pharmaceuticals | Image: Bluejay Therapeutics | Press Release
Related News: Mirum Pharmaceuticals Receives the US FDA Approval for Ctexli to Treat Cerebrotendinous Xanthomatosis
PharmaShots, your go-to media platform for customized news across multiple therapeutic areas. For more information, reach us at connect@pharmashots.com
